Autonomix Medical to Present Pancreatic Cancer Pain Data at EuroPCR 2026 — Autonomix Medical, Inc.

Event summary

Autonomix Medical had two abstracts accepted for presentation at EuroPCR 2026, focusing on pancreatic cancer pain mitigation.
The abstracts highlight long-term data on transvascular nerve-targeting technology for pain management.
EuroPCR 2026 takes place May 19–22, 2026, in Paris, France.
Autonomix's technology is investigational and not yet cleared for marketing in the U.S.

The big picture

Autonomix Medical's abstract acceptances at EuroPCR 2026 signal growing interest in its transvascular nerve-targeting platform, particularly for pancreatic cancer pain—a condition with limited treatment options. The company's technology, if validated, could disrupt traditional pain management approaches, potentially expanding into other nerve-related conditions. Success hinges on regulatory approval and sustained clinical evidence.

What we're watching

Clinical Validation: Whether long-term data will solidify Autonomix's position in pancreatic cancer pain mitigation.
Market Expansion: The pace at which Autonomix can expand its technology to other nerve-related conditions.
Regulatory Pathway: How quickly Autonomix can secure U.S. marketing clearance for its investigational technology.